Stockreport
Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff [The Motley Fool]
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff The biotech just announced a potentially game-changing acquisition. Vertex Pharmaceuticals ( NASDAQ:VRTX ) holds a virtual monopoly in treating cystic fibrosis (CF). But the successful biotech isn't content with winning in only one therapeutic area. Vertex is also developing drugs for treating pain in addition to other rare genetic diseases, including alpha-1 antitrypsin deficiency (AATD), beta-thalassemia, Duchenne muscular dystrophy, and sickle cell disease. Now Vertex has its eyes on its most ambitious goal ever: curing type 1 diabetes. The company announced on Tuesday that it's acquiring privately held Semma Therapeutics, which focuses exclusively on developing a cure for type 1 diabetes, for $950 million. Vertex is making a big bet, but it's one that just might have an astronomical payoff. Type 1 diabetes results when insulin-producing beta cells of the pancreatic islets (region
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | VRTX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
VRTX alerts
VRTX alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
NEWS
NEWS
- Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know [Yahoo! Finance][Yahoo! Finance]
- Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13[Business Wire]
- Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek [Yahoo! Finance][Yahoo! Finance]
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Scotiabank from $426.00 to $430.00. They now have a "sector perform" rating on the stock.[MarketBeat]
- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target lowered by analysts at Truist Financial Co. from $550.00 to $460.00. They now have a "buy" rating on the stock.[MarketBeat]
- More
VRTX
SEC Filings
SEC Filings
- 12/20/24 - Form 8-K
- 11/19/24 - Form 4
- 11/15/24 - Form 144
- VRTX's page on the SEC website
- More